Forxiga trial shows clinically meaningful improvements in glycemic control among patients aged 10–17 years

by

Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo. Adjusted mean change in A1C was −0.62% for Forxiga versus +0.41% for placebo, a difference of −1.03% (95% CI: -1.57-0.49; p

Leave A Comment

Your email address will not be published. Required fields are marked *